HomeCompareCMAXW vs ABBV

CMAXW vs ABBV: Dividend Comparison 2026

CMAXW yields 20833.33% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CMAXW wins by $78708720625850728448.00M in total portfolio value
10 years
CMAXW
CMAXW
● Live price
20833.33%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78708720625850728448.00M
Annual income
$77,972,479,019,762,930,000,000,000.00
Full CMAXW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CMAXW vs ABBV

📍 CMAXW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMAXWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMAXW + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMAXW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMAXW
Annual income on $10K today (after 15% tax)
$1,770,833.33/yr
After 10yr DRIP, annual income (after tax)
$66,276,607,166,798,485,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CMAXW beats the other by $66,276,607,166,798,485,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMAXW + ABBV for your $10,000?

CMAXW: 50%ABBV: 50%
100% ABBV50/50100% CMAXW
Portfolio after 10yr
$39354360312925364224.00M
Annual income
$38,986,239,509,881,460,000,000,000.00/yr
Blended yield
99.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CMAXW
No analyst data
Altman Z
-7.4
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMAXW buys
0
ABBV buys
0
No recent congressional trades found for CMAXW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMAXWABBV
Forward yield20833.33%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$78708720625850728448.00M$102.3K
Annual income after 10y$77,972,479,019,762,930,000,000,000.00$24,771.77
Total dividends collected$78660158496375930880.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CMAXW vs ABBV ($10,000, DRIP)

YearCMAXW PortfolioCMAXW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$2,094,033$2,083,333.33$11,550$430.00+$2.08MCMAXW
2$409,957,386$407,716,770.51$13,472$627.96+$409.94MCMAXW
3$75,037,124,826$74,598,470,422.36$15,906$926.08+$75037.11MCMAXW
4$12,841,257,574,210$12,760,967,850,647.00$19,071$1,382.55+$12841257.56MCMAXW
5$2,054,684,712,278,176$2,040,944,566,673,771.00$23,302$2,095.81+$2054684712.25MCMAXW
6$307,398,888,277,703,700$305,200,375,635,566,000.00$29,150$3,237.93+$307398888277.67MCMAXW
7$43,002,429,063,308,950,000$42,673,512,252,851,814,000.00$37,536$5,121.41+$43002429063308.91MCMAXW
8$5,625,127,515,678,174,000,000$5,579,114,916,580,434,000,000.00$50,079$8,338.38+$5625127515678174.00MCMAXW
9$688,076,267,371,778,200,000,000$682,057,380,930,002,500,000,000.00$69,753$14,065.80+$688076267371778176.00MCMAXW
10$78,708,720,625,850,720,000,000,000$77,972,479,019,762,930,000,000,000.00$102,337$24,771.77+$78708720625850728448.00MCMAXW

CMAXW vs ABBV: Complete Analysis 2026

CMAXWStock

CareMax, Inc. provides chronic disease management services through physicians and health care professionals. It offers a suite of health care and social services to its patients, including primary care, specialty care, telemedicine, health and wellness, optometry, dental, pharmacy, and transportation; and services to children and adults through Medicaid programs, as well as through commercial insurance plans. The company also provides CareOptimize, a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians in the United States. It operates multi-specialty medical care centers in Florida, Tennessee, Texas, and New York. The company is headquartered in Miami, Florida.

Full CMAXW Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CMAXW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMAXW vs SCHDCMAXW vs JEPICMAXW vs OCMAXW vs KOCMAXW vs MAINCMAXW vs JNJCMAXW vs MRKCMAXW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.